5439602025-04-012025-06-305439602025-04-012025-06-30in-capmkt:OtherExpenses1Member5439602025-04-012025-06-30in-capmkt:OtherExpenses2Member5439602025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15439602025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25439602025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss35439602025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss45439602025-04-012025-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543960CONCORDBIONAINE338H01029Concord Biotech LimitedMain BoardEquity2025-04-012026-03-312025-08-082025-08-04INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2025-08-0815:00:002025-08-0816:00:00Declaration of unmodified opinion2025-04-012025-06-30UnauditedConsolidated20398760001367760002176652000599099000128463000-276510000378974000586000177763000595882000160425700057239500005723950001407850005955000146740000042565500000014923000440578000-281880004123900004405780000412390000010461600014.214.21004.214.21 Notes to the statement of unaudited consolidated financial results for the quarter ended June 30 2025 <BR> <BR> 1. The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on August 8 2025.The Statutory Auditors of the company have carried out a limited review of the said results. <BR> <BR> 2. The figures for the quarter ended March 31 2025 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31 2024 which were subjected to limited review. <BR> <BR> 3.The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard Ind AS 108 Operating Segment. <BR> <BR> 4.The above consolidated financial results has been prepared in accordance with Indian Accounting Standards Ind AS notified under Section 133 of the Companies Act 2013 read together with Companies Indian Accounting Standards Rules 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India SEBI. <BR> <BR> 5. Subsequent to the quarter ended 30 June 2025, the Company has made an equity investment of USD 1,500 in Stellon Biotech Inc., USA. This investment represents the subscription of 15 million equity shares at a price of USD 0.0001 per share, resulting into 75 percent ownership stake in Stellon Biotech Inc. This transaction has no impact on the results for the quarter ended 30 June 2025.Power and Fuel294750000Other Expenses301132000Re-measurement gain/ (loss) on defined benefit plans-3207000Income tax relating to re-measurement gain/ (loss) on defined benefit plans807000Fair value changes on equity investments through OCI-34461000Income tax relating to fair value changes on equity investments through OCI8673000-2818800000-28188000UnauditedtrueB S R & Co. LLPtrue2028-07-31